WuXi Biologics shares up by over 62m after option exercises

WuXi Biologics (Cayman) Inc. reported a significant increase in its total issued shares for the month ended November 30, 2025. The company’s issued ordinary shares, excluding treasury shares, rose by 62,761,727, bringing the new total to 4,128,113,981. This increase was primarily driven by the exercise of Pre-IPO Share Option Schemes.

The exercises of share options, particularly from the Pre-IPO Share Option Schemes with various grant dates from 2016 to 2017 and exercise prices ranging from $0.1667 to $0.6000, generated total funds of $10,491,180.49 for the company during the month.

The company's authorized share capital remained unchanged at 6,000,000,000 ordinary shares, with a par value of $0.000008333333 per share, totaling $50,000. Additionally, no new shares were issued under the Restricted Share Award Scheme or the Share Award Scheme for Global Partner Program during the month, though significant numbers of shares remain eligible for future issuance under these schemes.